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Abstract
Combined exercise rehabilitation for chronic obstructive pulmonary disease (COPD) and chronic heart failure
(CHF) is potentially attractive. Uncertainty remains as to the baseline profiling assessments and outcome
measures that should be collected within a programme. Current evidence surrounding outcome measures
in cardiac and pulmonary rehabilitation were presented by experts at a stakeholder consensus event and all
stakeholders (n¼ 18) were asked to (1) rank in order of importance a list of categories, (2) prioritise outcome
measures and (3) prioritise baseline patient evaluation measures that should be assessed in a combined COPD
and CHF rehabilitation programme. The tasks were completed anonymously and related to clinical
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rehabilitation programmes and associated research. Health-related quality of life, exercise capacity and
symptom evaluation were voted as the most important categories to assess for clinical purposes (median
rank: 1, 2 and 3 accordingly) and research purposes (median rank; 1, 3 and 4.5 accordingly) within combined
exercise rehabilitation. All stakeholders agreed that profiling symptoms at baseline were ‘moderately’, ‘very’ or
‘extremely’ important to assess for clinical and research purposes in combined rehabilitation. Profiling of frailty
was ranked of the same importance for clinical purposes in combined rehabilitation. Stakeholders identified a
suite of multidisciplinary measures that may be important to assess in a combined COPD and CHF exercise
rehabilitation programme.
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Introduction
Chronic obstructive pulmonary disease (COPD) and
chronic heart failure (CHF) are long-term conditions,
characterised by exertional dyspnoea and fatigue.1,2
Exercise training is recommended in the management
of both diseases.2,3 Pulmonary rehabilitation (PR) is a
structured exercise programme, typically delivered
over 6–12 weeks, in which adults with respiratory
conditions participate in supervised exercise train-
ing.4 Programmes are interdisciplinary, often includ-
ing educational components that are designed to
optimise physical and social performance as well as
autonomy.4 The primary objective of PR is to
improve an individual’s exercise capacity to subse-
quently reduce their symptom burden, most com-
monly dyspnoea.5 Cardiac rehabilitation (CR) is
similar in structure to PR, however, prevention of
secondary cardiac events is the main objective.6 A
recent Cochrane Review examined exercise-based
CR specifically within CHF.7 While there is scientific
literature surrounding exercise rehabilitation for CHF,
often access is limited. This is in part reflected by the
recent national audit report which stated only 5.5% of
patients starting CR had CHF.8
Cardiovascular disease is a leading cause of mor-
bidity and mortality in COPD (particularly in those
with mild–moderate disease),9 suggesting some
patients with COPD may benefit from components
of CR, aiming to reduce cardiovascular risk. Conver-
sely, patients with CHF are likely to benefit from an
improved exercise capacity and the subsequent reduc-
tion in dyspnoea, the primary objectives of PR. The
systemic effects from COPD and CHF are similar,
such as skeletal muscle dysfunction.10 Individuals
with CHF have reduced functional capacity compared
to the traditional CR population and their level of
function is similar to adults with COPD.11 This fur-
ther supports merging CHF and COPD into one com-
bined exercise rehabilitation programme. Previous
research invited adults with CHF to PR alongside
adults with COPD, and it was found to be feasible
and effective.11 To the best of our knowledge, the
research by Evans et al.11 was the first to investigate
combined exercise rehabilitation for COPD and CHF;
a measure of exercise capacity was used as the pri-
mary outcome and no assessment of cardiovascular
risk was undertaken.
There have been suggestions as to the choice of
outcome measures that should be embedded within
CR12 and PR.5 The core outcome measures in effec-
tiveness trials initiative13 suggests a standard template
of outcomes for use in either CR or PR is not estab-
lished. In 2017, a study was registered to report on a
core set of outcomes within PR, but findings are not
yet available.14 Similar efforts are needed within CR.
In a 2016 consensus event, expert stakeholders
from cardiac and respiratory medicine discussed the
practical considerations and key components of a
combined exercise rehabilitation programme for
adults with COPD and/or CHF.15 The stakeholders
(n ¼ 74 including service providers, commissioners,
managers and researchers) concluded that rehabilita-
tion for COPD and CHF could be symptom as
opposed to disease-based. Specifically within the
United Kingdom, the long-term plan created by
the National Health Service (NHS) acknowledges the
opportunity of merging CR and PR, but state an
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evidence base for joint rehabilitation is required, prior
to promulgation across the NHS.16
An exploration of experts’ and stakeholders’ opin-
ion concerning outcome measures in a combined
exercise rehabilitation programme appears to be the
clear progression regards developing a combined
rehabilitation programme. The Delphi technique is
often used to gain consensus on a topic17 and is
important for achieving consensus on issues where
none previously existed.18 However, it can be time-
consuming and laborious.19 The technique consists of
various ‘rounds’ and it has previously been stated the
first stage is ‘characterized by exploration of the sub-
ject under discussion, wherein each individual contri-
butes additional information he feels is pertinent to
the issue’.20
The objective of this stakeholder event was to dis-
cuss and prioritise baseline and outcome measures
that should be collected within combined COPD and
CHF exercise rehabilitation. A patient and public
involvement (PPI) event was used to secure the opin-
ion of current service users.
Methods
Stakeholder consensus event
Invitations were sent to all experts and stakeholders
prior to the event which was held at the National
Institute for Health Research (NIHR) Leicester Bio-
medical Research Centre, Glenfield Hospital on 22
November 2017. The experts and stakeholders were
invited based on their previous experiences in
research and clinical practice in cardiac and respira-
tory disease. Prior to selection, we identified the
importance of representation of a range of healthcare
professionals, clinical leads from diverse geographi-
cal locations and a representation of a variety of ser-
vice delivery models. Event organisers (AVJ, RAE
and SJS) scoped the literature (systematic reviews,
Cochrane reviews and respective national audits) to
create a list of categories for discussion. This was
circulated to all stakeholders prior to the event and
comments/suggestions were welcomed. The final list
is listed in Table 1.
Experts presented on key categories before all
attendees were led through four different tasks
(Figure 1). An example question from each task is
shown in Online Supplemental Material 1. All stake-
holders were asked to rank the categories in the order
of overall importance, with 1 referring to the ‘most
important’ for both clinical (task 1) and research
purposes (task 2). Stakeholders were then asked ‘Do
you think a measure assessing (category) should be
used for clinical purposes?’and ‘Do you think a mea-
sure assessing (category) should be used for research
purposes?’ These were binary questions with yes or
no answers (task 3). All stakeholders were then asked
to rate the importance of each category as (a) a patient
Table 1. Categories that were discussed at consensus
event.
List of categories discussed
Health-related quality of life
Anxiety and depression
Exercise capacity
Frailty
Peripheral muscle assessment
Symptom evaluation
Cardiometabolic risk
Physical activity
Disease-specific knowledge
Self-efficacy
Functional capacity
Organ impairment
Carers’ engagement
Figure 1. A flow chart showing the tasks completed by
stakeholders at the consensus meeting.
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baseline/profiling measure and (b) an outcome mea-
sure for both clinical and research purposes using a 1–7
Likert-type scale (‘not at all important’, ‘low impor-
tance’, ‘slightly important’, ‘neutral’, ‘moderately
important’, ‘very important’ and ‘extremely important’)
(task 4). Answers were provided through a combination
of paper responses and electronic voting. Descriptive
statisticswere used to report consensus. Following anal-
ysis of results, general discussion then occurred sur-
rounding the top categories.
PPI event
The objective of the PPI event was to understand the
outcome measures deemed most important by current
service users and was held at the National Centre for
Sport and Exercise Medicine, Loughborough Univer-
sity on 7 February 2018. Patients currently enrolled
on the combined exercise rehabilitation programme at
University Hospital Leicester NHS Trust were
approached. Volunteers were provided with the same
list of categories from the stakeholder event
Figure 2. (a) The median ranking of each category for clinical rehabilitation purposes. A rank of 1 illustrates the most
important. (b) The median ranking of each category for research rehabilitation purposes. A rank of 1 illustrates the most
important.
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(functional status was written as ‘activities of daily
living’) and were asked which items they thought
were the most important to measure using an image-
based 1–7 Likert-type scale.21 Participants were asked
if a ‘generic/non-disease specific’ or ‘disease spe-
cific’ set of measures should be assessed within com-
bined rehabilitation. This was stated as measures that
assess your health/well-being in general or assess
aspects of your health/well-being that may be
impacted by your disease. Volunteers were informed
of the stakeholder consensus event but not the results.
Results
Stakeholder demographics
Twenty interdisciplinary stakeholders from across
England were invited to attend the 1-day meeting.
Five stakeholders were unable to attend the event,
of which three remotely completed data collection.
Despite efforts to ensure data completeness, the num-
ber of responses received for task 4 is shown in Online
Supplemental Material 2, Table A.
In total, consensus was gathered from 18 experts
and stakeholders across the United Kingdom (listed as
authors). The professions of stakeholders are as fol-
lows: clinician (n ¼ 6), nurse (n ¼ 3), physical activ-
ity specialist (n ¼ 1), physiotherapist (n ¼ 7) and
clinical scientist (n ¼ 1).
Over half of the stakeholders (55%, n ¼ 10) cur-
rently work within clinical CR and/or PR programmes
and 94% (n ¼ 17) are currently involved in research
within CR and/or PR. The majority of the stake-
holders were involved in the previous consensus
meeting15 (72%, n ¼ 13) and less than a quarter of
the stakeholders had developed an outcome measure
in the past (22%, n ¼ 4).
Overall ranking of categories that could be
assessed for clinical purposes in combined
rehabilitation programmes
Figure 2(a) shows the ranking of the median data from
18 stakeholders, which revealed that the five most
important categories that should be assessed for clin-
ical purposes were health-related quality of life, exer-
cise capacity, symptom evaluation, anxiety and
depression and self-efficacy. Organ impairment was
ranked the least important category to assess in clin-
ical rehabilitation programmes (median rank of 12).
Overall ranking of categories that could be
assessed for research purposes within combined
rehabilitation programmes
Figure 2(b) shows the categories considered the most
important by the stakeholders for research purposes.
These include health-related quality of life, exercise
capacity, symptom evaluation, frailty and joint fifth
were cardiometabolic risk and anxiety and
depression.
Health-related quality of life was ranked the most
important for clinical and research purposes (median
rank 2), while organ impairment was ranked the least
important (median rank of 12). The largest difference
between importance of categories for clinical and
research purposes was found in disease-specific
knowledge and cardiometabolic risk (median rank
differed by 3). Results show disease-specific knowl-
edge was ranked of higher importance for clinical
purposes, while cardiometabolic risk was deemed
more important for research purposes surrounding
combined rehabilitation. Frailty and peripheral mus-
cle assessment had a median rank difference of 2
(frailty clinical median rank of 7, research median
rank of 5; peripheral muscle assessment clinical med-
ian rank 11, research median rank of 9).
Categories that could be assessed for clinical and/
or research purposes in combined rehabilitation
programmes
Thirty-nine percent (n ¼ 7) of stakeholders voted to
assess organ impairment in research rehabilitation set-
tings alone (data not shown).
Baseline patient evaluation measures for clinical
purposes in combined rehabilitation programmes
A measure of health-related quality of life was
deemed ‘moderately’, ‘very’ or ‘extremely’ important
by 72% (n ¼ 13) of the stakeholders.
Nine stakeholders voted a measure of peripheral
muscle assessment was ‘not at all’, ‘low’, ‘slightly’
important or they were neutral in their decision. Six
stakeholders voted similarly for measures of self-
efficacy.
Outcome measures for clinical purposes
in combined rehabilitation programmes
Ninety-four percent (n ¼ 17) of stakeholders voted
health-related quality of life and exercise capacity
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as ‘moderately’, ‘very’ or ‘extremely’ important to
assess as outcome measures in clinical rehabilitation
settings. The majority of stakeholders also agreed that
physical activity, functional capacity and symptom
evaluation were ‘moderately’, ‘very’ or ‘extremely’
important outcome markers (89%, 88% and 94%,
respectively). There was a range of opinion with
regard to the assessment of some items; over a third
of stakeholders (n ¼ 6) voted a measure of organ
impairment was ‘not at all’ or of ‘low’ importance,
while 41% (n¼ 7) voted ‘moderately’ or ‘very impor-
tant’. Additionally, half of the stakeholders (50%, n¼
9) voted peripheral muscle assessment was ‘moder-
ately’, ‘very’ or ‘extremely’ important, while over a
quarter (28%, n¼ 5) suggested it was ‘not at all’ or of
‘low’ importance to assess as an outcome measure in
clinical rehabilitation settings.
Baseline patient evaluation measures for
research purposes in combined rehabilitation
programmes
Measures of organ impairment, anxiety and depres-
sion and health-related quality of life were also
deemed important (82% (n ¼ 14), 83% (n ¼ 15)
and 69% (n ¼ 11) voted ‘moderately’, ‘very’ or
‘extremely’ important, accordingly). A quarter (n ¼
4) of stakeholders voted disease-specific knowledge
was ‘slightly’, ‘low’ or ‘not at all’ important in
this setting.
Outcome measures for research purposes
in combined rehabilitation programmes
Health-related quality of life and anxiety and depres-
sion also scored highly, with 89% (n ¼ 16) and 82%
(n ¼ 14) of the stakeholders voting the same impor-
tance. Forty-seven per cent (n ¼ 8) of stakeholders
deemed an outcome measure of organ impairment in
research as ‘slightly’, ‘low’ or ‘not at all’ important’.
PPI event
Results were collected from six of the eight attendees;
two adults were unable to complete the task despite
support. Two participants voted a measure of health-
related quality of life, two voted a measure of exercise
capacity and two equally voted a measure of physical
activity and activities of daily living as the most
important. Eighty-three per cent (n ¼ 5) of partici-
pants agreed that a generic set of measures or
measures relating to both the heart and the lungs
should be assessed in all patients on a combined
COPD and CHF exercise rehabilitation programme.
General discussion and practicalities of assessing
domains
Once the results had been analysed, a general discus-
sion was encouraged between stakeholders, which
included the practicality and possible methods to
assess each item. A summary of the items prioritised
for both clinical and research purposes surrounding
combined rehabilitation is summarised in Table 2,
alongside specific comments and possible measure-
ment tools. The stakeholders note this is not an
exhaustive list of measurement tools, and it was
beyond the scope of the meeting to describe the valid-
ity of measures. This report provides recommenda-
tions for assessment and acknowledges further work
is needed regards the validity of these tools within a
specific cardio-respiratory population. Scientific
statements,22 programme guidelines23 and stan-
dards24,25 have been produced by various professional
bodies and the stakeholders acknowledged that
adhering to these may influence outcome measures
collected.
Stakeholders agreed that where possible, question-
naires should be generic and not disease specific, as
many patients are likely to attend the programme with
co-morbid conditions. Existing questionnaires should
not be altered to make them generic. Instead, ques-
tionnaires need to be validated in other populations.
While an assessment of cardiometabolic risk did not
rank within the top five most important items within
clinical settings, stakeholders suggested measures of
blood pressure, lipid profile, glycated haemoglobin
(HbA1c) and components of the metabolic syndrome
could be assessed as they are clinically relevant and
applicable to the setting. Use of a cardiovascular dis-
ease risk calculator (such as QRISK2-201753) was
also discussed; however, this is not recommended in
adults with existing cardiac disease.
Discussion
Summary of main findings
To the best of our knowledge, this is the first stake-
holder event seeking to identify and prioritise the out-
come measures and baseline patient evaluation
measures that could be used within combined COPD
and CHF rehabilitation, for both clinical and research
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purposes. Health-related quality of life was ranked by
stakeholders as the most important category to assess
for clinical and research purposes within rehabilita-
tion, with measures of exercise capacity and symptom
evaluation also rated highly. This is supported by the
views of service users in that they also stated health-
related quality of life and exercise capacity were
important outcome measures. A previous Delphi
panel including 26 experts from 13 countries which
aimed to develop a consensus-based core outcome
measures within multimorbidity research also found
health-related quality of life to be the highest scored
outcome.54
We saw discordance in the ranking of assessing
cardiometabolic risk in that it was ranked highly for
research purposes but lower for clinical purposes.
There is inconclusive evidence surrounding the effect
of traditional rehabilitation on cardiometabolic vari-
ables, some studies have found improvements in hae-
modynamic and lipid profile55–57 whereas others have
not.58,59 Many review articles have suggested this is
an area of future research.60–62
Skeletal muscle dysfunction is well recognised in
COPD and CHF10 and is a frequently reported mea-
sure in PR studies, although less commonly in CHF
rehabilitation studies. Interestingly, the measurement
Table 2. Top five categories to assess within clinical and research exercise rehabilitation programmes for adults with
COPD and/or CHF as voted by stakeholders.a
Top five categories to assess Comment/proposed methods
Clinical
1. Health-related quality of life Largely generic questionnaire, such as the potential use of the EuroQol 5D-3L,26
EuroQol 5D-5L,27 World Health Organisation quality of life (WHOQOL)-
10028,29 or WHOQOL-BREF30
2. Exercise capacity Six minute walk test (6MWT),31 incremental shuttle walk test (ISWT),32 constant
work rate test33 and endurance shuttle walk test (ESWT)34 suggested measures
to assess exercise capacity
3. Symptom evaluation Breathlessness, fatigue, pain and sleep disturbance suggested as highly relevant
symptoms.
Examples: fatigue severity scale,35 functional assessment of chronic illness
therapy-fatigue (FACIT-F),36 medical research council (MRC) dyspnoea scale,37
dyspnoea 12 (D-12)38 and multidimensional dyspnoea profile (MDP)39
4. Anxiety and depression Hospital anxiety and depression scale (HADS)40
5. Self-efficacy Discussion was not specific for self-efficacy but importance of using generic
measures and tools was underlying
Research
1. Health-related quality of life Stakeholders explored the use of disease specific questionnaires that could be
applied to both conditions. For example, there is high similarity between the
chronic heart questionnaire (CHQ)41 and chronic respiratory questionnaire
(CRQ),42 with only one question differing between the two. A self-report
version of the CHQ and CRQ is available43,44
2. Exercise capacity Direct measure of oxygen consumption (VO2) may be beneficial within research.
6MWT,31 ISWT,32 constant work rate test33 and ESWT34 suggested as practical
assessments of exercise capacity
3. Symptom evaluation Breathlessness, fatigue, pain and sleep disturbance suggested as highly relevant
symptoms.
Discussed the potential for using integrated palliative care outcome scale
(IPOS)45
4. Frailty An assessment of physical frailty is most appropriate. Timed up and go test,46
clinical frailty scale,47 4-metre gait speed,48 short physical performance battery
(SPPB) may be appropriate, though ceiling and floor effects are acknowledged49
Joint 5th Anxiety and depression/
cardiometabolic risk
HADS40
Coronary calcification,50 pulse wave velocity51 and fibrinogen levels52 as markers
of cardiometabolic risk
COPD: chronic obstructive pulmonary disease; CHF: chronic heart failure.
aAdditional comments or proposed methods of assessment are also provided.
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of peripheral muscle strength was ranked of low
importance for both clinical and research purposes
within rehabilitation. However, there is suggestion
from the American Thoracic Society and European
Respiratory Society that measures of limb muscle
function are important within COPD.63 While stake-
holders were not asked to reason their decisions, there
was agreement surrounding the importance of a func-
tional assessment of strength, such as the sit-to-stand
test, as opposed to specific assessment of muscle
strength or mass.
All stakeholders voted that profiling frailty and symp-
toms were ‘moderately’, ‘very’, or ‘extremely’ impor-
tant for clinical purposes within combined
rehabilitation. Research surrounding frailty and PR has
increased over recent years, yet it remains a novel out-
come.Frailty affects one in four patientswithCOPD that
are referred for PR and has been found to be an indepen-
dent predictor of programme non-completion.64 Within
the CHF population, a systematic review found the pre-
valence of frailty ranged from18% to 54% and those that
were frail were more likely to experience higher rates of
morbidity andmortality.65 Unfortunately, assessment of
frailty within CR is not frequently reported.66
Our preliminary findings support the need for suit-
able symptom-based outcome measures to be applied
across the cardio-respiratory spectrum, particularly
within the COPD and CHF population. Many of the
categories deemed important by stakeholders (e.g.
exercise capacity, frailty and cardiometabolic risk)
are arguably easy to assess, irrespective of the disease.
For example, an exercise test can be used to examine
exercise tolerance or a blood sample can be analysed
to quantify cardiometabolic risk. These are universal
assessments that can be used to assess features of
many diseases. Challenges arise with respect to cer-
tain outcomes, such as assessing health-related
quality of life. Many generic tools exist, such as
Short-Form 36.67 These may not acknowledge the
symptoms often experienced by cardio-respiratory
patients, but this is an area of future research. Most
widely used tools are disease specific, designed and
validated for use in either COPD or CHF populations.
An example of this is the chronic heart question-
naire41 and chronic respiratory questionnaire42 used
in CHF and COPD populations accordingly, despite
only one question differing between the two question-
naires. There is an opportunity to explore the value of
tools that can be useful in both cardiac and respiratory
disease, or indeed the multi-morbid patient. An exam-
ple of this is the multidimensional dyspnoea profile,
which was validated in an asthma, COPD, pneumonia
and CHF cohort.39
Strengths and limitations of the study
We acknowledge that the stakeholders and PPI repre-
sentatives only included UK participants, therefore, a
risk of sampling bias may be present; extending this
process to collaborate with international centres is an
important future work. The degree of international
generalisability is compromised. We also recognise
that the PPI representatives may be influenced by their
participation in a combined rehabilitation programme,
as opposed to being exposed toCRor PRonly. Further-
more, this stakeholder event does not meet all the
requirements of common consensus methodology
(e.g. Delphi, Nominal Group Technique). Despite this,
the stakeholder event was characterised by most of the
features, including anonymity, statistical group
response and the use of experts.68 This strengthens our
findings by reducing domination of individual partici-
pants, providing a statistical summary of the group’s
view and the inclusion of experts from various aca-
demic, clinical and research backgrounds.
Implications for future research and clinical
practice
Combined rehabilitation for adults with COPD and/or
CHF is a potentially attractive deliverymodel. Research
has shown it is feasible and effective to rehabilitate
adults with CHF alongside adults with COPD,11 and it
may have economical and clinical benefits.15 However,
merging two rehabilitation programmes together raises
questions and concerns regards the assessments and
outcome measures that should be included. This con-
sensus event has created a priority list of measures for a
combined exercise rehabilitation programme that is
likely to guide the delivery of future clinical practice
and research within this novel area.
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